This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally

Vestal Point acquired 4,500,000 shares of Terns Pharmaceuticals in the fourth quarter. The quarter-end position value increased by $181.80 million as a result of this purchase, which created a new stake for the fund.